ImmunityBio Faces Securities Fraud Lawsuit

Berger Montague Law Firm Files Class Action on Behalf of Investors

Apr. 15, 2026 at 1:37pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a gavel, and a magnifying glass arranged on a clean white background, conceptually representing the legal proceedings surrounding the alleged securities fraud case against ImmunityBio.A legal battle over alleged securities fraud casts a shadow of scrutiny over the biotech firm.Malvern Today

National plaintiffs' law firm Berger Montague PC has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026 through March 24, 2026. The lawsuit alleges that the company's Chief Scientific and Medical Officer materially overstated the capabilities of ImmunityBio's Anktiva platform, rendering prior statements about the company's business, operations, and prospects materially false and misleading.

Why it matters

This lawsuit highlights the importance of transparency and accurate disclosures for publicly traded companies. Investors rely on the information provided by companies to make informed decisions, and any misrepresentation or omission of material facts can have significant financial consequences for those who purchase shares.

The details

According to the lawsuit, ImmunityBio, headquartered in San Diego, Calif., develops cancer immunotherapies and vaccines. The lawsuit alleges that the company's Chief Scientific and Medical Officer made statements that overstated the capabilities of ImmunityBio's Anktiva platform, leading to the company's prior statements about its business, operations, and prospects being materially false and misleading. As a result, investors who purchased shares during the Class Period suffered losses when the true state of the company was revealed.

  • The Class Period is from January 19, 2026 through March 24, 2026.
  • The investor deadline to seek to be appointed as a lead plaintiff representative of the class is May 26, 2026.

The players

Berger Montague PC

A national plaintiffs' law firm that is leading the class action lawsuit against ImmunityBio.

ImmunityBio, Inc.

A San Diego-based company that develops cancer immunotherapies and vaccines.

Got photos? Submit your photos here. ›

What they’re saying

“Investors who purchased or acquired ImmunityBio securities during the Class Period may, no later than May 26, 2026, seek to be appointed as a lead plaintiff representative of the class.”

— Andrew Abramowitz, Attorney, Berger Montague

“Investors who purchased or acquired ImmunityBio securities during the Class Period may, no later than May 26, 2026, seek to be appointed as a lead plaintiff representative of the class.”

— Caitlin Adorni, Attorney, Berger Montague

What’s next

Investors who purchased or acquired ImmunityBio securities during the Class Period have until May 26, 2026 to seek to be appointed as a lead plaintiff representative of the class.

The takeaway

This lawsuit highlights the importance of accurate and transparent disclosures by publicly traded companies. Investors rely on the information provided by companies, and any misrepresentation or omission of material facts can have significant financial consequences. The outcome of this case will likely have broader implications for the biotechnology industry and the standards of disclosure expected from companies.